Oxurion NV (OXUR) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.097x

Based on the latest financial reports, Oxurion NV (OXUR) has a cash flow conversion efficiency ratio of 0.097x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.16 Million ≈ $-1.36 Million USD) by net assets (€-11.99 Million ≈ $-14.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oxurion NV market cap and net worth for the company's overall valuation and market capitalisation.

Oxurion NV - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Oxurion NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Oxurion NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Oxurion NV ranked by their cash flow conversion efficiency. Explore how high is Oxurion NV's earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Exploitasi Energi Indonesia
JK:CNKO
-0.075x
Tan Delta Systems PLC
LSE:TAND
-0.245x
EGF THERAMED HEALTH CORP.
F:AUH
N/A
K3 Business Technology Group PLC
LSE:KBT
0.278x
Panamax AG
F:ICP
N/A
Aquila Energy Efficiency Trust PLC
LSE:AEET
-0.027x
Kazera Global PLC
LSE:KZG
-0.041x
First Eagle Alternative Capital BDC Inc
NYSE:FCRX
0.022x

Annual Cash Flow Conversion Efficiency for Oxurion NV (2006–2024)

The table below shows the annual cash flow conversion efficiency of Oxurion NV from 2006 to 2024. View OXUR share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €-11.06 Million
≈ $-12.93 Million
€-2.07 Million
≈ $-2.42 Million
0.187x -74.75%
2023-12-31 €-13.19 Million
≈ $-15.42 Million
€-9.77 Million
≈ $-11.42 Million
0.741x -83.04%
2022-12-31 €-4.58 Million
≈ $-5.36 Million
€-20.02 Million
≈ $-23.40 Million
4.367x -82.18%
2021-12-31 €-1.11 Million
≈ $-1.30 Million
€-27.16 Million
≈ $-31.75 Million
24.508x +2365.49%
2020-12-31 €25.05 Million
≈ $29.28 Million
€-27.10 Million
≈ $-31.68 Million
-1.082x -85.42%
2019-12-31 €53.31 Million
≈ $62.32 Million
€-31.10 Million
≈ $-36.36 Million
-0.583x -97.46%
2018-12-31 €105.31 Million
≈ $123.12 Million
€-31.12 Million
≈ $-36.38 Million
-0.295x -249.85%
2017-12-31 €133.36 Million
≈ $155.91 Million
€26.30 Million
≈ $30.74 Million
0.197x +206.66%
2016-12-31 €109.86 Million
≈ $128.44 Million
€-20.31 Million
≈ $-23.74 Million
-0.185x -13.08%
2015-12-31 €170.01 Million
≈ $198.77 Million
€-27.79 Million
≈ $-32.49 Million
-0.163x +27.00%
2014-12-31 €208.01 Million
≈ $243.19 Million
€-46.58 Million
≈ $-54.46 Million
-0.224x -325.38%
2013-12-31 €258.77 Million
≈ $302.53 Million
€25.71 Million
≈ $30.06 Million
0.099x -18.50%
2012-12-31 €227.97 Million
≈ $266.52 Million
€27.79 Million
≈ $32.49 Million
0.122x +173.54%
2011-12-31 €118.03 Million
≈ $137.99 Million
€-19.56 Million
≈ $-22.87 Million
-0.166x -36.00%
2010-12-31 €138.19 Million
≈ $161.56 Million
€-16.84 Million
≈ $-19.69 Million
-0.122x +5.59%
2009-12-31 €93.72 Million
≈ $109.57 Million
€-12.10 Million
≈ $-14.14 Million
-0.129x -167.36%
2008-12-31 €62.39 Million
≈ $72.94 Million
€11.96 Million
≈ $13.98 Million
0.192x +162.73%
2007-12-31 €48.44 Million
≈ $56.63 Million
€-14.80 Million
≈ $-17.30 Million
-0.306x -28.03%
2006-12-31 €35.28 Million
≈ $41.24 Million
€-8.42 Million
≈ $-9.84 Million
-0.239x --

About Oxurion NV

BR:OXUR Belgium Biotechnology
Market Cap
$248.85K
€212.86K EUR
Market Cap Rank
#31276 Global
#112 in Belgium
Share Price
€0.00
Change (1 day)
-7.69%
52-Week Range
€0.00 - €0.02
All Time High
€102000.00
About

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more